Parallax Volatility Advisers, L.P. Global Blood Therapeutics, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $602,580 - $974,292	24,200 Added 48.21%	74,400 $2.18 Million
Q3 2021 Nov 15, 2021	SELL	$25.48 - $37.34 $1.28 Million - $1.87 Million	-50,200 Reduced 50.0%	50,200 $1.28 Million
Q2 2021 Aug 16, 2021	BUY	$32.46 - $43.42 $2.49 Million - $3.33 Million	76,800 Added 325.42%	100,400 $3.52 Million
Q1 2021 May 14, 2021	BUY	$38.94 - $50.85 $23,364 - $30,510	600 Added 2.61%	23,600 $962,000
Q4 2020 Feb 16, 2021	BUY	$37.65 - $63.77 $865,950 - $1.47 Million	23,000 New	23,000 $996,000
Q4 2019 Feb 14, 2020	SELL	$45.7 - $81.86 $859,160 - $1.54 Million	-18,800 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$45.35 - $57.91 $2.1 Million - $2.68 Million	-46,200 Reduced 71.08%	18,800 $912,000
Q2 2019 Aug 14, 2019	SELL	$52.6 - $63.29 $1.84 Million - $2.22 Million	-35,000 Reduced 35.0%	65,000 $3.42 Million
Q1 2019 May 15, 2019	BUY	$39.99 - $53.48 $163,959 - $219,268	4,100 Added 4.28%	100,000 $5.29 Million
Q4 2018 Feb 14, 2019	BUY	$31.54 - $46.67 $2.08 Million - $3.08 Million	65,900 Added 219.67%	95,900 $3.94 Million
Q3 2018 Nov 14, 2018	BUY	$38.0 - $51.1 $1.14 Million - $1.53 Million	30,000 New	30,000 $1.14 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.